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JMJD6 is a tumorigenic factor and therapeutic
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Chromosome 17q21-ter is commonly gained in neuroblastoma, but it is unclear which gene in
the region is important for tumorigenesis. The JMJD6 gene at 17q21-ter activates gene
transcription. Here we show that JMJD6 forms protein complexes with N-Myc and BRD4,
and is important for E2F2, N-Myc and c-Myc transcription. Knocking down JMJD6 reduces
neuroblastoma cell proliferation and survival in vitro and tumor progression in mice, and high
levels of JMJD6 expression in human neuroblastoma tissues independently predict poor
patient prognosis. In addition, JMJD6 gene is associated with transcriptional super-enhancers.
Combination therapy with the CDK7/super-enhancer inhibitor THZ1 and the histone dea-
cetylase inhibitor panobinostat synergistically reduces JMJD6, E2F2, N-Myc, c-Myc
expression, induces apoptosis in vitro and leads to neuroblastoma tumor regression in
mice, which are significantly reversed by forced JMJD6 over-expression. Our findings
therefore identify JMJD6 as a neuroblastoma tumorigenesis factor, and the combination
therapy as a treatment strategy.
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Neuroblastoma is the most prevalent solid tumor in earlychildhood, and accounts for ~15% of all childhood cancerdeath1. Unlike adult cancers, the most prominent features
of human neuroblastoma are gene deletion, amplification, or
gain1.
The most common gene copy number variation in human
neuroblastoma is chromosome 17q21-ter gain, which predicts
poor patient prognosis2. The genes survivin and insulin growth
factor 2 binding protein 1 within this chromosomal region have
been shown to promote neuroblastoma cell survival and increase
MYCN mRNA expression, respectively3,4. However, it is not clear
which genes at 17q21-ter are critical for neuroblastoma
tumorigenesis.
The jumonji domain-containing 6 (JMJD6) gene at chromo-
some 17qter is a dual arginine demethylase and lysyl hydroxylase
of histone and nonhistone proteins5,6. As a histone arginine
demethylase, JMJD6 upregulates target gene transcription by
forming a protein complex with BRD4 and demethylating histone
H4 at arginine 3 (H4R3) at target gene antipause enhancers,
leading to RNA polymerase II (RNA Pol II) release from
promoter-proximal pause regions and aberrant gene expression
in glioblastoma7,8. As a lysyl hydroxylase, JMJD6 forms a protein
complex with p53 and catalyzes p53 protein hydroxylation,
leading to p53 inactivation, colon cancer cell proliferation and
survival9. As such, targeting the demethylase or hydroxylase
activity of JMJD6 alone is not an ideal strategy for effective cancer
therapy.
One of the most promising anticancer strategies is to suppress
oncogene transcription by disrupting associated transcriptional
super-enhancers. Transcriptional super-enhancers are found
selectively at the loci of oncogenes and are therefore ideal targets
for cancer therapy10,11. THZ1, a specific covalent inhibitor of
CDK7, selectively blocks the transcription of super-enhancer-
associated oncogenes, such as MYC, MYCN, YAP1, and RUNX1,
thereby inducing cancer cell growth inhibition and apoptosis. In
this regard, THZ1 has been shown to inhibit leukemia, lung
cancer, MYCN gene-amplified neuroblastoma, and esophageal
squamous cell carcinoma progression in mice12–15.
In this study, we have found that the JMJD6 gene is gained in
~80% of human neuroblastoma tissues. JMJD6 formed protein
complexes with N-Myc and the transcriptional coactivator BRD4.
Suppression of JMJD6 resulted in decreased E2F2, N-Myc, and
c-Myc gene expression, reduced neuroblastoma cell proliferation,
induction of apoptosis in vitro, and inhibition of tumor growth
in vivo. While JMJD6 is associated with super-enhancers, treat-
ment with THZ1 and the histone deacetylase (HDAC) inhibitor
panobinostat synergistically reduced JMJD6, E2F2, N-Myc, and
c-Myc expression, induced tumor cell apoptosis in vitro, and led
to neuroblastoma tumor regression in mice, which were sig-
nificantly reversed by forced JMJD6 overexpression, suggesting
this combination as a therapeutic approach for neuroblastoma.
Results
High JMJD6 in neuroblastomas predicts poor patient prognosis.
The JMJD6 gene, located at chromosome 17qter, is one of the few
histone modification genes located within the 17q21-ter region. We
analyzed the human neuroblastoma array comparative genomic
hybridization (array-CGH) datasets from 209 patients16–18 and the
matched tumor tissue microarray gene expression Kocak dataset
including the 209 patients18, both published previously and
downloaded from the Gene Expression Omnibus website of the
National Center for Biotechnology Information (SuperSeries
GSE45480). Analysis of the datasets showed that the JMJD6 gene
was gained in every human neuroblastoma tissue with 17q gain,
and that chromosome 17q/JMJD6 gene was gained in 172 of the
total of 209 (82.30%), including 21 of 26MYCN amplified (80.77%)
and 149 of 181 MYCN-non-amplified (82.32%), human neuro-
blastoma tissues (Fig. 1a, b). For the two human neuroblastoma
tissues with unknownMYCN amplification status, 17q/JMJD6 gene
was gained in both of the samples.
We next examined whether chromosome 17q segmental gain
and numerical (whole chromosome) gain had different effects on
17q copy number and JMJD6 gene expression. While tumors with
17q segmental gain or numerical gain showed higher 17q copy
number than tumors without 17q gain, tumors with 17q
segmental gain also showed significantly higher 17q copy number
than tumors with 17q numerical gain (Fig. 1c). Consistent with
these data, JMJD6 gene expression was significantly higher in
tumors with 17q segmental gain than in tumors with 17q
numerical gain or without 17q gain, and there was no difference
in JMJD6 gene expression between tumors with 17q numerical
gain and tumors without 17q gain (Fig. 1d).
To assess the clinical relevance of JMJD6 in human
neuroblastoma tissues, expression of JMJD6, as well as N-Myc
and c-Myc, was examined in the publicly available microarray
gene expression Versteeg19 and Oberthuer18,20 datasets consisting
of 88 and 476 human neuroblastoma patient samples with
prognosis information, respectively. Two-sided Pearson’s correla-
tion study showed that JMJD6 mRNA expression positively
correlated with N-Myc mRNA expression in the 88 and 476
human neuroblastoma tissues of the Versteeg and Oberthuer
datasets (Supplementary Fig. 1a), and that JMJD6 mRNA
expression positively correlated with c-Myc mRNA expression
in the 405MYCN-non-amplified human neuroblastoma tissues of
the large Oberthuer dataset (Supplementary Fig. 1b). Since N-
Myc and c-Myc mutually suppress each other’s expression, and
N-Myc and c-Myc mRNA expression is well known to inversely
correlate with each other in human neuroblastoma tissues21, we
used the higher value of N-Myc and c-Myc expression as the N-
Myc/c-Myc expression value (two Myc as a group) for each of the
476 human neuroblastoma tissues. Two-sided Pearson’s correla-
tion study revealed that JMJD6 mRNA expression positively
correlated with N-Myc/c-Myc mRNA expression with a good
effect size (R= 0.447) in the 476 neuroblastoma tissues (Fig. 1d).
Kaplan–Meier survival analysis showed that high levels of
JMJD6 mRNA expression in human neuroblastoma tissues were
associated with poor prognosis in the 88 and the 476
neuroblastoma patients of the Versteeg and the Oberthuer
datasets, respectively (p < 0.0001) (Fig. 1e). Furthermore, high
levels of JMJD6 mRNA expression in the 405 MYCN-non-
amplified and the 66 MYCN-amplified neuroblastoma tissues
were also positively associated with poor patient overall survival
in the large Oberthuer dataset (Fig. 1f). Importantly, using the
median or upper quartile of JMJD6 mRNA expression as the cut-
off points, multivariable Cox regression analysis showed that high
levels of JMJD6 mRNA expression was associated with poor
patient overall survival and event-free survival, independent of
disease stage, age at the time of diagnosis and MYCN
amplification status (Table 1), and the current key prognostic
markers for neuroblastoma patients22.
In comparison, Kaplan–Meier survival analysis of the 209
human neuroblastoma patients with array-CGH data showed that
chromosome 17q gain, when samples with segmental or
numerical gain were combined, did not associate with patient
overall survival (Supplementary Fig. 1c). When tumors with
chromosome 17q segmental gain or numerical gain were analyzed
separately, 17q segmental gain was associated with poor patient
overall survival, whereas 17q numerical gain was not associated
with patient overall survival (Supplementary Fig. 1d). In addition,
the MXRA7 gene is immediately upstream of the JMJD6 gene at
chromosome 17qter and gained in the same manner as the JMJD6
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gene (Fig. 1a). Using the optimal Kaplan scanning, the median,
upper or lower quartile of MXRA7 mRNA expression as the cut-
off points, Kaplan–Meier survival analysis showed that high levels
of MXRA7 mRNA expression in human neuroblastoma tissues
were not associated with poor overall survival, but were
associated with better prognosis, in the 88 and the 476
neuroblastoma patients of the Versteeg and the Oberthuer
datasets, respectively (Supplementary Fig. 2a, b).
Taken together, the data suggest that the JMJD6 gene is
commonly gained in human neuroblastoma tissues, and that a
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high level of JMJD6 expression independently predicts poor
patient prognosis.
Myc upregulates JMJD6 by binding to its gene promoter. Myc
oncoproteins induce gene transcription by direct binding to
canonical and noncanonical E-boxes at target gene promoters23.
Our bioinformatics analysis identified canonical (CACGTG)
(−186 to −181) and noncanonical (CACGCG) (−81 to −76bp)
E-boxes upstream of the JMJD6 gene transcription start site. We
therefore examined whether N-Myc and c-Myc modulated JMJD6
gene expression in CHP134 (chromosome 17q21-ter/JMJD6
gained and MYCN amplified) and SK-N-AS (chromosome 17q21-
ter/JMJD6 gained andMYCN-non-amplified) neuroblastoma cells.
As shown in Fig. 2a, b, transfection of CHP134 cells with N-Myc
siRNA-1 or N-Myc siRNA-2 efficiently knocked down N-Myc
mRNA and protein expression, and reduced JMJD6 mRNA and
protein expression. Similarly, transfection of SK-N-AS cells with c-
Myc siRNA-1 or c-Myc siRNA-2 efficiently knocked down c-Myc
mRNA and protein expression, and reduced JMJD6 mRNA and
protein expression (Fig. 2a, b and Supplementary Fig. 3a). Con-
sistent with these findings, withdrawal of doxycycline (DOX) from
cell culture media of SHEP Tet/21N cells, which are stably
transfected with a tetracycline/DOX withdrawal-inducible N-Myc
expression construct, increased N-Myc and JMJD6 mRNA and
protein expression (Fig. 2c).
We next performed chromatin immunoprecipitation (ChIP)
assays with an anti-N-Myc or anti-c-Myc antibody or control
IgG, and real-time PCR with primers targeting the JMJD6 gene
region (Fig. 2d). The ChIP assays showed that the N-Myc and
c-Myc antibodies efficiently immunoprecipitated the E-box
region, compared with the negative control or exon 2 region
(Fig. 2e). Taken together, the data suggest that N-Myc and c-Myc
upregulate JMJD6 gene expression via binding to the JMJD6 gene
promoter.
JMJD6 induces E2F2, Myc, and their target gene expression. As
an arginine demethylase, JMJD6 is known to induce target
gene transcription by interacting with the transcriptional coacti-
vator bromodomain protein BRD4 and demethylating histone
H4R3 at target gene enhancers7. We performed protein co-
immunoprecipitation assays with an anti-BRD4 or JMJD6 anti-
body or control IgG in CHP134 cells. Immunoblot analysis
showed that the anti-BRD4 and anti-JMJD6 antibodies efficiently
immunoprecipitated both BRD4 and JMJD6 proteins (Fig. 3a),
suggesting that JMJD6 forms a protein complex with BRD4 in
neuroblastoma cells.
We next established CHP134 and SK-N-AS cells stably
expressing DOX-inducible control shRNA, JMJD6 shRNA-1 or
JMJD6 shRNA-2 FH1tUTG construct (Fig. 3b)24. Affymetrix
microarray experiments were performed in DOX-inducible
control shRNA, JMJD6 shRNA-1, and JMJD6 shRNA-2
CHP134 cells 40 h after treatment with vehicle control or DOX.
Differential expression analysis identified a number of genes
upregulated or downregulated after JMJD6 gene knockdown
including E2F2, which was downregulated, following the induc-
tion of JMJD6 shRNA-1 and JMJD6 shRNA-2 (Supplementary
Data 1). We also performed Affymetrix microarray experiments
in DOX-inducible control shRNA and JMJD6 shRNA-2 SK-N-AS
cells 40 h after treatment with vehicle control or DOX.
Differential gene expression and gene set enrichment analysis
Fig. 1 High JMJD6 gene expression in neuroblastoma tissues predicts poor patient prognosis. a, b Array-CGH data were employed to examine chromosome
17q and JMJD6 gene gain in 209 human neuroblastoma tissues. The frequencies of chromosome gain at different regions of chromosome 17q were plotted
against genomic locations in the 209 neuroblastoma tissues a. The Venn diagram showed overlap between JMJD6 gene gain andMYCN gene amplification
or nonamplification in the human neuroblastoma tissues b. c, d Chromosome 17q copy number (c) and JMJD6 gene expression (d) were examined among
the 209 human neuroblastoma tissues according to 17q segmental gain, numerical gain, or no gain. JMJD6 gene expression was obtained from the Kocak
microarray gene expression dataset. The center line was the median, the ends of the box were the upper and lower quartiles, and the whiskers were set to
the minimum and maximum value within ±1.5 × the interquartile range (***p < 0.001, ns: not significant, one-way ANOVA). e Two-sided Pearson’s
correlation was employed to analyze the correlation between JMJD6 and N-Myc/c-Myc mRNA expression in the 476 human neuroblastoma tissues of the
microarray gene expression Oberthuer dataset. The higher value of N-Myc and c-Myc expression was used as the N-Myc/c-Myc expression value for each
of the neuroblastoma tissues. f, g Kaplan–Meier curves showed the probability of overall survival of patients according to JMJD6 mRNA expression levels
in the 88 and 476 neuroblastoma samples in the Versteeg and Oberthuer datasets f, or in the 66 MYCN-amplified and 405 MYCN-non-amplified
neuroblastoma samples in the large Oberthuer dataset g, using the optimal cut-off level determined by Kaplan scanning and two-sided log-rank tests.
Source data are provided as a Source Data file
Table 1 Multivariable Cox regression analysis of factors prognostic for patient survivala
Factors Overall survival Event-free survival
HR (95% CI) p-value HR (95% CI) p-value
High JMJD6 expression (median level as the cut off) 1.87 (1.16–3.02) 0.010 1.52 (1.04–2.20) 0.029
MYCN amplification 3.24 (2.05–5.11) 6.1E–5 1.76 (1.18–2.62) 0.005
Age > 18 months 3.44 (1.88–6.30) 2.6E–05 1.75 (1.19–2.59) 0.005
Stages 3 and 4b 3.14 (1.55–6.35) 0.002 2.38 (1.57–3.62) 4.8E-05
High JMJD6 expression (upper quartile as the cut off) 4.58 (2.15–9.74) 7.8E–5 1.56 (1.06–2.29) 0.024
MYCN amplification 3.19 (2.05–4.96) 2.6E–7 1.82 (1.23–2.68) 0.003
Age > 18 months 3.20 (1.77–5.78) 1.2E–04 1.77 (1.21–2.60) 0.004
Stages 3 and 4b 2.83 (1.41–5.66) 0.003 2.38 (1.57–3.61) 4.4E-05
aThe level of JMJD6 expression was considered high or low in relation to the median or upper quartile level of expression in tumors of the Oberthuer dataset. Hazard ratios were calculated as the antilogs
of the regression coefficients in the proportional hazards regression. Multivariable Cox regression analysis was carried out following the inclusion of the four above listed factors into the Cox regression
model, and p-value was obtained from two-sided log-rank test
bTumor stage was categorized as favorable (International Neuroblastoma Staging System stages 1, 2, and 4 S) or unfavorable (International Neuroblastoma Staging System stages 3 and 4). Source data
are provided as a Source Data file
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(GSEA) revealed that the transcription factor binding site
consistently repressed after JMJD6 knockdown in both CHP134
and SK-N-AS cell lines was the binding site for E2F (Supple-
mentary Tables 1, 2).
To examine whether JMJD6 directly regulates gene tran-
scription, we performed ChIP sequencing (ChIP-Seq) experi-
ments in DOX-inducible JMJD6 shRNA-2 CHP134 cells. The
ChIP-Seq data identified a list of genes with considerably
a
c
b
d
C
0–2000
JMJD6 gene promoter
–100
A B
Amplicon TSS
E-Box
(CACGCG)
E-Box
(CACGTG)
–200 1000
e
JMJD6
N-Myc
Actin
+ –
SH
EP
 
75
50
50
ChIP assays - CHP134
(N-Myc Ab/control IgG)
ChIP assays - SK-N-AS
(c-Myc Ab/control IgG)
N-Myc
siRNA-1
F
ol
d 
ch
an
ge
in
 N
-M
yc
 m
R
N
A
F
ol
d 
ch
an
ge
in
 J
M
JD
6 
m
R
N
A
F
ol
d 
en
ric
hm
en
t o
f
JM
JD
6 
ge
ne
 p
ro
m
ot
er
F
ol
d 
en
ric
hm
en
t o
f
JM
JD
6 
ge
ne
 p
ro
m
ot
er
N-Myc
JMJD6
Actin
30 2.0
1.5
1.0
0.5
0.0
15 4
3
2
***
*** ***
*** ***
*** ***
***
**
***
1
0
10
5
0
20
10
0
DO
X
Ve
hic
le
DO
X
Ve
hic
le
CHP134
75
50
50
SK-N-AS
c-Myc
JMJD6
Actin
c-Myc
siRNA-1
50
50
50
1.5
CHP 134 CHP 134 SK-N-AS SK-N-AS
1.2
0.9
0.6
0.3
0.0
Co
nt
ro
l s
iR
NA
N-
M
yc
 si
RN
A-
1
N-
M
yc
 si
RN
A-
2
Co
nt
ro
l s
iR
NA
N-
M
yc
 si
RN
A-
1
N-
M
yc
 si
RN
A-
2
Am
pli
co
n 
A
Am
pli
co
n 
B
Am
pli
co
n 
C
Am
pli
co
n 
A
Am
pli
co
n 
B
Am
pli
co
n 
C
Co
nt
ro
l s
iR
NA
c-
M
yc
 si
RN
A-
1
c-
M
yc
 si
RN
A-
2
Co
nt
ro
l s
iR
NA
c-
M
yc
 si
RN
A-
1
c-
M
yc
 si
RN
A-
2
F
ol
d 
re
du
ct
io
n
in
 N
-M
yc
 g
en
e
ex
pr
es
si
on
F
ol
d 
re
du
ct
io
n
in
 c
-M
yc
 g
en
e
ex
pr
es
si
on
F
ol
d 
re
du
ct
io
n
in
 J
M
JD
6 
ge
ne
ex
pr
es
si
on
1.5
1.2
0.9
0.6
0.3
0.0
1.5
1.2
0.9
0.6
0.3
0.0
1.2
0.9
0.6
0.3
0.0
F
ol
d 
re
du
ct
io
n
in
 J
M
JD
6 
ge
ne
ex
pr
es
si
on
N-Myc
siRNA-2
SHEP Tet/21N SHEP Tet/21N
Control
siRNA
c-Myc
siRNA-2
Control
siRNA
DOX
Te
t/2
1N
Fig. 2 N-Myc and c-Myc upregulate JMJD6 expression by binding to the JMJD6 promoter. a, b CHP134 cells were transfected with control siRNA, N-Myc
siRNA-1 or N-Myc siRNA-2, and SK-N-AS cells were transfected with control siRNA, c-Myc siRNA-1, or c-Myc siRNA-2. Forty-eight hours later, RNA and
protein were extracted for RT-PCR (a) and immunoblot (b) analyses. Error bars represent normalized standard errors from three independent experiments
(**p < 0.01, ***p < 0.001, one-way ANOVA). c SHEP Tet/21N cells were treated with DOX (2 µg/ml) or vehicle control for 48 h. RT-PCR and immunoblot
analyses were conducted. Error bars represent normalized standard errors from three independent experiments (***p < 0.001, two-tailed unpaired
Student’s t test). d Schematic representation of the JMJD6 gene promoter. TSS indicates transcription start site. Amplicons A, B, and C represented the
sites for ChIP PCR primers. e ChIP assays were performed with a control IgG, anti-N-Myc or anti-c-Myc antibody (Ab), followed by PCR with primers
targeting a remote negative control region (amplicon A), the E-box region (amplicon B), or the exon 2 region (amplicon C) of the JMJD6 gene in CHP134
and SK-N-AS cells. Fold enrichment of the JMJD6 gene region was calculated as the difference in cycle thresholds obtained with the anti-N-Myc or anti-c-
Myc Ab compared with the control IgG, relative to input. Error bars represent normalized standard errors from three independent experiments (*p < 0.05,
**p < 0.01, two-tailed unpaired Student’s t test). Source data are provided as a Source Data file
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11132-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3319 | https://doi.org/10.1038/s41467-019-11132-w |www.nature.com/naturecommunications 5
reduced RNA Pol II binding peaks at their gene promoters
(Supplementary Data 2). GSEA analysis of the repressed genes
showed that the top four gene sets were G2M checkpoint genes,
E2F target genes, mitotic spindle genes, and Myc target genes
(Supplementary Table 3). While the MYCN gene was not short-
listed as one of the genes with loss of RNA Pol II binding peaks
at promoters in Supplementary Data 2, ChIP-Seq and ChIP
PCR data revealed 60% reduction in RNA Pol II binding at the
MYCN gene promoter after JMJD6 knockdown (Supplementary
Fig. 3b–d).
We next examined whether JMJD6 regulated E2F2, N-Myc,
and c-Myc expression. DOX-inducible control shRNA, JMJD6
shRNA-1 or JMJD6 shRNA-2 CHP134, and SK-N-AS cells were
treated with vehicle control or DOX. Real-time reverse
transcription PCR (RT-PCR) and immunoblot analyses con-
firmed that knocking down JMJD6 significantly reduced E2F2,
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N-Myc and c-Myc mRNA, and protein expression in CHP134
and SK-N-AS cells (Fig. 3c). Consistent with these data,
transfection with JMJD6 siRNA-1 or siRNA-2 reduced N-Myc
and c-Myc mRNA and protein expression (Supplementary
Fig. 3e, f), and transfection with a JMJD6 open reading frame
(ORF) expression construct led to E2F2, N-Myc, and c-Myc
upregulation (Fig. 3d), in CHP134 or SK-N-AS cells. While
JMJD6 has been shown to activate gene transcription through
forming a protein complex with BRD47 and BRD4 is well known
to regulate N-Myc and c-Myc gene transcription25,26, treatment
with the small molecule BRD4 inhibitor OTX015 also
considerably reduced E2F2 expression in CHP134 and SK-N-
AS cells (Supplementary Fig. 3g). In addition, c-Myc is known to
directly induce E2F2 gene transcription by binding to Myc-
responsive element E-boxes at the E2F2 gene promoter27. In
CHP134 and SK-N-AS cells, knocking down N-Myc or c-Myc
with two independent siRNAs significantly reduced E2F2
mRNA and protein expression (Supplementary Fig. 4a, b).
Conversely, upregulation of N-Myc by DOX withdrawal in
SHEP Tet/21N cells upregulated E2F2 mRNA and protein
expression (Supplementary Fig. 4c, d).
Since both JMJD6 and N-Myc are known to activate gene
transcription7,14, we examined whether JMJD6 formed a protein
complex with N-Myc in cells and whether JMJD6 directly binds
to N-Myc. Protein co-immunoprecipitation and immunoblot
analyses showed that an anti-N-Myc antibody efficiently
immunoprecipitated both JMJD6 and N-Myc proteins in
CHP134 cells (Fig. 3e). Different N-Myc protein fragments
(1–86, 82–254, 249–358, 336–400, and 400–464 amino acids)
were then cloned into the pGEX-2T construct, in frame with N-
terminal GST. GST pull-down assays showed that JMJD6 protein
was bound to the N-Myc 82–254 amino acid fragment (Fig. 3f),
demonstrating that JMJD6 protein directly binds to the Myc Box
II region of N-Myc protein.
To further demonstrate the JMJD6-N-Myc protein complex,
we performed ChIP-Seq with anti-JMJD6 and anti-N-Myc
antibodies in CHP134 cells. Bioinformatics analysis showed that
both JMJD6 and N-Myc protein were bound to super-enhancers,
typical enhancers, as well as promoters. Importantly, the majority
of super-enhancers and typical enhancers bound by JMJD6 were
also bound by N-Myc, and ~47% of promoters bound by JMJD6
were also bound by N-Myc (Fig. 3g, Supplementary Data 3–5).
Taken together, our data suggest that JMJD6 forms a protein
complex with BRD4 and N-Myc, and therefore regulates E2F2
and Myc expression as well as E2F and Myc target gene
expression.
JMJD6 induces neuroblastoma cell proliferation and survival.
As JMJD6 regulates Myc and E2F2 expression, we examined
whether JMJD6 modulates neuroblastoma cell proliferation, sur-
vival, and clonogenic capacity. CHP134 and SK-N-AS cells were
transfected with control siRNA, JMJD6 siRNA-1 or JMJD6
siRNA-2. Alamar blue assays showed that knocking down JMJD6
reduced the number of viable CHP134 and SK-N-AS cells
(Fig. 4a). As the JMJD6 siRNAs targeted the 5′-untranslated
region of JMJD6, CHP134 and SK-N-AS cells stably transfected
with an empty vector or JMJD6 ORF expression construct were
transfected with control siRNA, JMJD6 siRNA-1 or JMJD6
siRNA-2. Alamar blue assays showed that forced overexpression
of JMJD6 largely reversed the effect of JMJD6 siRNAs in reducing
the number of viable neuroblastoma cells (Fig. 4b). Similarly,
treatment with DOX resulted in a significant decrease in the
number of viable DOX-inducible JMJD6 shRNA-1 and
JMJD6 shRNA-2, but not DOX-inducible control shRNA,
CHP134, and SK-N-AS cells (Supplementary Fig. 5a, b). Cell
cycle analysis showed that treatment with DOX had no effect on
the percentage of DOX-inducible control shRNA CHP134 and
SK-N-AS cells at each phase of the cell cycle, but significantly
increased the percentage of DOX-inducible JMJD6 shRNA-1 and
JMJD6 shRNA-2 CHP134 and SK-N-AS cells at the sub-G1 phase
and decreased the percentage of cells at the S phase (Fig. 4c and
Supplementary Fig. 5c, d).
Colony formation assays were also performed. As shown in
Fig. 4d, treatment with DOX did not have an effect on clonogenic
capacity in DOX-inducible control shRNA, but considerably
diminished clonogenic capacity in DOX-inducible JMJD6
shRNA-1 and JMJD6 shRNA-2, CHP134 and SK-N-AS cells.
Taken together, the data suggest that JMJD6 is required for
neuroblastoma cell proliferation, survival, and tumorigenic
capacity.
JMJD6 is important for neuroblastoma progression in vivo. To
determine whether JMJD6 is important for E2F2 and Myc
expression and neuroblastoma progression in vivo, DOX-
inducible JMJD6 shRNA-2 SK-N-AS cells were xenografted into
mice, and the mice were fed food with or without DOX.
The DOX treatment group displayed considerably slower
tumor growth in comparison to the control treatment group
(Fig. 5a). Survival curve analysis showed that DOX treatment,
compared with control treatment, significantly increased the
probability of survival in mice xenografted with DOX-inducible
JMJD6 shRNA-2 cells by twofold (Fig. 5b). Immunoblot analysis
showed that DOX treatment, compared with vehicle control
treatment, significantly decreased JMJD6 protein expression in
DOX-inducible JMJD6 shRNA SK-N-AS cell tumors (Fig. 5c, d).
Protein expression of the JMJD6 targets, E2F2 and c-Myc, was
also reduced in the DOX treatment group, compared with the
vehicle control treatment group (Fig. 5c, d). The data
Fig. 3 JMJD6 forms complexes with N-Myc and BRD4 to induce E2F2 and Myc expression. a Protein extracted from CHP134 cells was immunoprecipitated
(IP) overnight with 2.5 μg of control IgG, anti-JMJD6 or anti-BRD4 antibody (Ab). The immunoprecipitated protein was immunoblotted with anti-JMJD6 or
anti-BRD4 Ab. b, c DOX-inducible control shRNA, JMJD6 shRNA-1 or JMJD6 shRNA-2 CHP134, and SK-N-AS cells were treated with vehicle control or
DOX for 48 h, followed by RT-PCR analysis of JMJD6 mRNA (b), or RT-PCR and immunoblot analysis of JMJD6, N-Myc, c-Myc, and E2F2 mRNA and
protein (c). Error bars represent normalized standard errors from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, two-tailed unpaired
Student’s t test). d Protein was extracted from CHP134 and SK-N-AS cells stably transfected with an empty vector or JMJD6 expression construct, followed
by immunoblot analysis. e Protein extracted from CHP134 cells was subjected to IP overnight with 5 μg of control IgG or anti-N-Myc Ab, followed by
immunoblot analysis with anti-JMJD6 or anti-N-Myc Ab. f Immobilized GST-N-Myc protein fragments were incubated with equal amounts of nuclear
protein prepared from HEK-293T cells transiently transfected with the recombinant vector pCMV14-JMJD6_3 × Flag. Pulled-down complexes were probed
with a monoclonal anti-Flag antibody, and Ponceau staining detected by ChemiDoc MP was used as loading controls. g DNA-protein complex was
extracted from CHP134 cells for ChIP sequencing with anti-JMJD6 and anti-N-Myc antibodies. Numbers inside the Venn diagram indicated the numbers of
peaks at super-enhancers, typical enhancers, and promoters, which were bound by JMJD6 or N-Myc, and the overlap between them. Source data are
provided as a Source Data file
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Fig. 4 JMJD6 is important for neuroblastoma cell proliferation, survival, and colony formation. a CHP134 and SK-N-AS cells were transfected with control
siRNA, JMJD6 siRNA-1 or JMJD6 siRNA-2 for 96 h, followed by Alamar blue assays. Error bars represent normalized standard errors from three
independent experiments (**p < 0.01, ***p < 0.001, one-way ANOVA). b CHP134 and SK-N-AS cells stably transfected with an empty vector or JMJD6
open reading frame (ORF) expression construct were transfected with control siRNA, JMJD6 siRNA-1 or JMJD6 siRNA-2, followed by Alamar blue assays.
Error bars represent normalized standard errors from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA). c DOX-
inducible control shRNA, JMJD6 shRNA-1 or JMJD6 shRNA-2 CHP134, and SK-N-AS cells were treated with control or DOX for 72 h, followed by staining
with propidium iodide and flow cytometry analysis of the cell cycle. The percentage of cells at each phase of the cell cycle was calculated. Error bars
represent standard errors from three independent experiments (*p < 0.05, two-tailed unpaired Student’s t test). d DOX-inducible control shRNA, JMJD6
shRNA-1 or JMJD6 shRNA-2 CHP134, and SK-N-AS cells were treated with vehicle control or DOX for 14 days. Tumor cells were stained with crystal violet
and the numbers of colonies were counted. Error bars represent normalized standard errors from three independent experiments (*p < 0.05, **p < 0.01,
***p < 0.001, two-tailed unpaired Student’s t test). Source data are provided as a Source Data file
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demonstrate that JMJD6 is important for E2F2 and Myc
expression, neuroblastoma tumor progression, and mouse
survival in vivo.
THZ1 and panobinostat synergistically reduce JMJD6 expression.
Critical oncogenes are characterized by association with transcrip-
tional super-enhancers that induce massive oncogene
overexpression10,14. We performed ChIP-Seq with anti-acetylated
histone H3 lysine 27 (H3K27ac), anti-trimethyl H3K4 (H3K4me3),
and anti-monomethyl H3K4 (H3K4me) antibodies in CHP134 cells.
We also analyzed the published anti-H3K27ac antibody ChIP-Seq
data from SK-N-AS cells, which were deposited at Gene Expression
Omnibus website (Series GSE90683)28. The ChIP-Seq data revealed
that the MXRA7/JMJD6 gene locus was associated with H3K27
acetylation and H3K4 monomethylation but not with H3K4 tri-
methylation (Fig. 6a, b), markers for transcriptional super-
enhancers. ChIP PCR showed that CDK7 bound more abun-
dantly to the MXRA7/JMJD6 gene super-enhancer region than the
JMJD6 gene promoter region (Supplementary Fig. 6a).
We then investigated the effect of the CDK7/super-enhancer
inhibitor THZ1 on JMJD6 and MXRA7 gene expression. RT-PCR
and immunoblot analyses showed that treatment with THZ1
reduced JMJD6 and N-Myc expression in CHP134 cells, and
JMJD6 and c-Myc expression in SK-N-AS cells (Fig. 6c), but
showed no effect on MXRA7 expression (Supplementary Fig. 6b).
The data suggest that the MXRA7/JMJD6 gene super-enhancers
activate the transcription of the JMJD6 but not MXRA7 gene.
Since BET bromodomain inhibitors and HDAC inhibitors are
known to synergistically reduce oncogene expression29, we
examined whether combination therapy with THZ1 and the HDAC
inhibitor panobinostat synergistically reduced JMJD6, Myc and their
target E2F2 expression. RT-PCR and immunoblot analyses showed
that JMJD6, N-Myc, c-Myc, and E2F2 mRNA and protein were all
more significantly reduced by the THZ1 and panobinostat
combination treatment, compared with single-agent treatment
(Fig. 6d and Supplementary Fig. 7a, b). Thus, the data suggest that
the JMJD6 gene is associated with transcriptional super-enhancers,
and that THZ1 and panobinostat combination therapy synergisti-
cally reduces JMJD6, N-Myc, c-Myc, and E2F2 expression.
THZ1 and panobinostat synergistically suppress neuroblastoma.
We next examined the synergistic effects of THZ1 and panobi-
nostat in inhibiting neuroblastoma cell proliferation and survival.
Alamar blue assays showed that treatment with THZ1 in combi-
nation with panobinostat for 72 h significantly decreased the
numbers of viable CHP134 and SK-N-AS cells, compared with
treatment with THZ1 or panobinostat alone (Fig. 7a). Isobologram
analysis confirmed that the combination was indeed synergistic, as
the combination indexes were well below 1.0 (Fig. 7b). We next
examined whether JMJD6 was required for the anticancer effects of
JMJD6
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Fig. 5 JMJD6 is important for E2F2 and Myc expression and tumor progression in vivo. a DOX-inducible JMJD6 shRNA-2 SK-N-AS cells were xenografted
into nude mice. When tumors reached 0.05 cm3 in volume, the mice were divided into two groups, and fed with food with or without 600mg/kg of DOX.
Tumor growth was monitored every other day, and the mice were culled when tumor reached 1 cm3. Error bars represent standard errors (**p < 0.01, two-
tailed paired Student’s t test). b Survival curve analysis showed the probability of mouse overall survival. Two-sided log-rank test was used to generate the
p-value. c, d Protein was extracted from the tumors from the mice, and subjected to immunoblot analysis of JMJD6, c-Myc, and E2F2 protein expression
(c), followed by quantification against the house-keeping actin using Quantity One software (d). Error bars represent standard errors (**p < 0.01, ***p <
0.001, two-tailed unpaired Student’s t test). Source data are provided as a Source Data file
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this combination therapy, by treating CHP134 and SK-N-AS cells
stably transfected with an empty vector or JMJD6 ORF expression
construct with THZ1 and panobinostat, either alone or in com-
bination. Alamar blue assays showed that overexpression of JMJD6
partially reversed the reduction in the number of viable neuro-
blastoma cells after treatment with THZ1 and panobinostat com-
bination therapy (Fig. 7c). In addition, cell cycle analysis revealed
that THZ1 and panobinostat synergistically increased the percen-
tage of cells at the sub-G1 phase in both CHP134 and SK-N-AS
cells (Fig. 7d and Supplementary Fig. 7c, d).
We lastly xenografted SK-N-AS neuroblastoma cells stably
transfected with an empty vector or JMJD6 ORF expression
construct into nude mice, and treated these mice with vehicle
control, THZ1, panobinostat or combination, when tumors
reached 0.05 cm3. As shown in Fig. 7e, treatment with THZ1 or
panobinostat alone reduced tumor growth in mice xenografted
with empty vector SK-N-AS cells and treatment with panobino-
stat alone reduced tumor growth in mice xenografted with SK-N-
AS cells transfected with JMJD6 ORF. Importantly, THZ1 and
panobinostat combination therapy synergistically reduced tumor
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progression and resulted in tumor regression in mice xenografted
with empty vector SK-N-AS cells, but only moderately suppressed
tumor progression in mice xenografted with SK-N-AS cells
transfected with JMJD6 ORF (Fig. 7e). Immunoblot analysis of
tumor tissues from the mice showed that THZ1 and panobinostat
cooperatively reduced JMJD6 and E2F2 protein expression only
in mice xenografted with empty vector SK-N-AS cells, and that
transfection with the JMJD6 ORF expression construct led to
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Fig. 7 THZ1 and panobinostat synergistically induce tumor regression by reducing JMJD6. a, b CHP134 and SK-N-AS cells were treated with vehicle control,
THZ1, panobinostat, or their combination for 72 h, followed by Alamar blue assays (a). Error bars represent normalized standard errors from three
independent experiments. Isobolograms showed the actual concentrations of THZ1 and panobinostat required to achieve inhibition of cell viability by 85%
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f Protein was extracted from the tumor tissues, and subjected to immunoblot analysis of JMJD6 and E2F2 protein expression. Source data are provided as a
Source Data file
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considerable JMJD6 and E2F2 protein overexpression and
nonresponse to THZ1 and panobinostat therapy (Fig. 7f). Our
data therefore demonstrate that THZ1 and panobinostat
combination therapy synergistically blocks neuroblastoma pro-
gression and induces tumor regression by blocking JMJD6
expression.
Discussion
Unlike adult cancers, neuroblastoma is characterized by frequent
chromosome copy number variations, such as chromosome
17q21-ter gain1. However, it is not clear which gene or genes at
17q21-ter plays key oncogenic roles. In this study, by analyzing
matched human neuroblastoma tissue array-CGH and gene
expression datasets, we have confirmed that 17q21-ter/JMJD6
gene is gained in the majority of MYCN-amplified and non-
amplified human neuroblastoma tissues, and that 17q segmental
gain leads to higher 17q copy number and higher JMJD6 gene
expression than 17q numerical gain and 17q no gain. Impor-
tantly, chromosome 17q segmental gain and high levels of JMJD6,
but not 17q numerical gain or high levels of MXRA7, the gene
immediately upstream of JMJD6 at chromosome 17qter, in neu-
roblastoma tissues correlate with poor patient prognosis. In
addition, our data demonstrate that JMJD6 overexpression in
neuroblastoma tissues predicts poor patient prognosis, indepen-
dently of other prognostic markers such as MYCN amplification
status, age at the time of diagnosis, and disease stage.
We have found positive correlation between JMJD6 and
N-Myc/c-Myc expression in human neuroblastoma tissues. We
have also identified Myc-responsive element E-boxes at the
JMJD6 gene core promoter, confirmed N-Myc and c-Myc protein
binding to the JMJD6 gene core promoter, and demonstrated
upregulation of JMJD6 by N-Myc and c-Myc. As N-Myc and c-
Myc are well known to induce gene transcription by binding to
Myc-responsive element E-boxes at target gene promoters23,30,
our data suggest that N-Myc and c-Myc overexpression in human
neuroblastomas further increases JMJD6 expression, even in
JMJD6 gene-gained cells.
In this study, our genome-wide differential gene expression
and GSEA analyses reveal that knocking down JMJD6 con-
siderably reduces the expression of E2F target genes and the E2F2
gene. ChIP-Seq data and GSEA analysis show that knocking
down JMJD6 significantly reduces RNA Pol II binding to E2F and
Myc target gene promoters. Importantly, we have confirmed that
JMJD6 protein forms a complex with BRD4 protein in neuro-
blastoma cells, that JMJD6 protein directly binds to N-Myc
protein at the Myc Box II region, and that the majority of super-
enhancers, typical enhancers, and promoters bound by JMJD6 are
also bound by N-Myc. In the literature, N-Myc regulates gene
transcription mainly through binding to target gene promoters
and enhancers14,30, and JMJD6 activates gene transcription by
interacting with MED12 in the mediator complex, interacting
with BRD4 at antipause enhancers and binding to gene
promoters7,31–33. Our data therefore suggest that JMJD6 activates
gene transcription partly through binding to N-Myc, and that the
interaction between JMJD6 and N-Myc is likely to be important
for efficient gene transcription.
While E2F and Myc are well-known tumorigenic factors, we
have confirmed that knocking down JMJD6 considerably reduces
neuroblastoma cell proliferation, induces apoptosis, and drama-
tically reduces clonogenic capacity. Consistent with these in vitro
data, knocking down JMJD6 reduces E2F2 and Myc expression,
suppresses tumor progression, and improves survival in mice.
The data suggest that high levels of JMJD6 expression due to
chromosome 17q21-ter segmental gain contributes to neuro-
blastoma pathogenesis.
Currently no small molecule JMJD6 inhibitors are available.
We have found that the JMJD6 gene is associated with tran-
scriptional super-enhancers in JMJD6 gene-gained neuroblastoma
cells, and that treatment with the CDK7 inhibitor THZ1, which
specifically targets super-enhancer associated oncogenes12–14,
significantly reduces JMJD6, N-Myc, and c-Myc expression.
While HDAC inhibitors are among the anticancer agents that
exert the best synergistic anticancer effects with BET bromodo-
main inhibitors, through synergistically reducing oncogene
expression29, we have confirmed that combination therapy with
THZ1 and the HDAC inhibitor panobinostat synergistically
reduces JMJD6, N-Myc, c-Myc, and E2F2 expression and neu-
roblastoma cell proliferation, and synergistically induces neuro-
blastoma cell death, which can be partly blocked by JMJD6
overexpression. In neuroblastoma-bearing mice, THZ1 and
panobinostat cooperatively reduce JMJD6 and E2F2 expression,
blocks tumor progression, and results in tumor regression, and
that forced JMJD6 overexpression in neuroblastoma cells sig-
nificantly blocks the in vivo anticancer effects of THZ1 and
panobinostat combination therapy. Our data therefore confirm
the critical role of JMJD6 in neuroblastoma tumorigenesis. As the
CDK7 inhibitor SY-1365 is currently in clinical trials in cancer
patients [https://clinicaltrials.gov/ct2/show/NCT03134638] and
the HDAC inhibitor panobinostat is currently in clinical practice,
our findings identify CDK7 inhibitor and HDAC inhibitor
combination therapy as a treatment strategy for neuroblastoma.
Methods
Cell culture. SK-N-AS, SHEP Tet/21N, and 293T embryonic kidney cells were
cultured in DMEM supplemented with 10% fetal calf serum. CHP134 cells were
cultured in Roswell Park Memorial Institute Medium 1640 with 10% fetal calf
serum and 1% l-glutamine. A total of 293T cells were obtained from the American
Type Culture Collection 20 years ago. CHP134 and SK-N-AS cells were obtained
from the European Collection of Cell Cultures and Sigma Aldrich in 2010. Cells
were confirmed to be free from mycoplasma contamination, and cell line identity
was verified in 2014–2018 by small tandem repeat profiling conducted at the
Garvan Institute of Medical Research or Cellbank Australia.
DOX-inducible control shRNA or JMJD6 shRNA cell lines. The lentiviral DOX-
inducible GFP-IRES-shRNA FH1tUTG construct was provided by Dr. Marco
Herold24 and used to generate control shRNA and JMJD6 shRNA expression
constructs. Control shRNA, JMJD6 shRNA-1, and JMJD6 shRNA-2 target
sequences were GCACTACCAGAGCTAACTCAGATAGTACT, CGAAGCTATT
ACCTGGTTTAA, and ATGGACTCTGGAGCGCCTAAA, respectively. Sense and
antisense control shRNA, JMJD6 shRNA-1, and JMJD6 shRNA-2 oligoes were
cloned into the DOX-inducible GFP-IRES-shRNA FH1tUTG construct. The DOX-
inducible GFP-IRES-control shRNA, JMJD6 shRNA-1 or JMJD6 shRNA-2 con-
struct was transfected into 293T cells. Viral media were collected to infect CHP134
and SK-N-AS neuroblastoma cells with polybrene (Santa Cruz Biotechnology,
Santa Cruz, CA) for 72 h. Cells with high GFP protein expression were selected by
fluorescence-activated cell sorting with BD FACS Jazz™ II Cell Sorter (BD Bios-
ciences, Franklin Lakes, NJ). For inducing shRNA expression in vitro, the cells were
treated with 2 µg/ml DOX every 24 h.
siRNA transfection. Target sequences of siRNAs were: 5′-AATGTGAATA
GTGCCAAGAAA-3′ (siRNA-1) and 5′-TGACAGAGCCCAAGAATGATT-3′
(siRNA-2) (Qiagen, Hamburg, Germany) for JMJD6; 5′-CGTGCCGGAGTTGGT
AAAGAA-3′ (siRNA-1) and 5′-TCCAGCGAGCTGATCCTCAAA-3′ (siRNA-2)
(Qiagen) for N-Myc; and 5′-CGGUGCAGCCGUAUUUCUATT-3′ (siRNA-1) and
5′-GGAACUAUGACCUCGACUATT-3′ (siRNA-2) for c-Myc. Negative control
siRNAs did not target any human genes (All Stars Negative Control siRNA,
Qiagen).
Neuroblastoma cells were transfected with siRNAs while plated onto 24- or 6-
well plates or T25 flasks using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Forty-eight hours later, RNA or
protein was harvested for analyses.
JMJD6 overexpressing neuroblastoma cell lines. EF1a-empty vector-IRES2-
mCherry-IRES-Puromycin-Lv224 and EF1a-JMJD6-IRES2-mCherry-IRES-Pur-
omycin-Lv224 expression constructs were purchased from GeneCopoeiaTM (Cat-
alog number EX-E2359-Lv224, GeneCopoeiaTM, Rockville, MD). The constructs
were transfected into 293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA). Viral media were collected to infect CHP134 and SK-N-AS neuroblastoma
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cells with polybrene (Santa Cruz Biotechnology, Santa Cruz, CA) for 72 h. Cells
with high mCherry protein expression were selected by fluorescence-activated cell
sorting with BD FACS Jazz™ II Cell Sorter (BD Bioscience).
Real-time reverse transcription PCR. RNA was extracted from tumor cells with
RNeasy Plus Mini Kit (Qiagen), followed by quantification with a Nanodrop
spectrophotometer (Thermo Fisher Scientific, Waltham, MA), according to the
manufacturer’s instructions. cDNAs were synthesized with random hexonucleotide
primers and Moloney murine leukemia virus reverse transcriptase (Invitrogen).
RT-PCR was performed with Power SYBR Green Master Mix (Invitrogen) as the
fluorescent dye and gene specific primers using Applied Biosystems 7900 (Applied
Biosystems, Grand Island, NY). No template controls were employed for detecting
nonspecific amplification. The sequences of RT-PCR primers were: 5′-CGACCAC
AAGGCCCTCAGTA-3′ (forward) and 5′-CAGCCTTGGTGTTGGAGGAG-3′
(reverse) for N-Myc; 5′-GGATTTTTTTCGGGTAGTGGAA-3′ (forward) and 5′-
TTCCTGTTGGTGAAGCTAACGTT-3′ (reverse) for c-Myc; 5′- GATCCAGAC
TCGCACTGGAC-3′ (forward) and 5′- CCCGAGGTCAGAGGTTTGTT-3′
(reverse) for JMJD6; 5′-GGCCAAGAACAACATCCAGT-3′ (forward) and 5′-
CGTGTTCATCAGCTCCTTCA-3′(reverse) for E2F2; and 5′-AGGCCAACCGCG
AGAAG-3′ (forward) and 5′-ACAGCCTGGATAGCAACGTACA-3′ (reverse) for
Actin. The primers were synthesized by Sigma (Sigma, Sydney, Australia). The
comparative threshold cycle (△△Ct) method was employed to quantify fold
changes in the expression of target genes34, relative to the housekeeping gene actin.
Immunoblot. Protein was extracted from tumor cells with radio-
immunoprecipitation assay buffer (150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris-Cl pH 7.5) containing protease inhibitors
(Sigma, St Louis, MO, USA). Supernatant was collected after the samples were
centrifugated at 13,000 × g at 4 °C for 20 min. Protein concentrations in the
supernatant samples were quantified with the Bicinchoninic Acid Assay kit (Pierce,
Rockford, IL).
For immunoblotting, protein samples were loaded onto sodium dodecyl sulfate-
polyacrylamide gels, followed by electrophoresis and transfer to nitrocellulose
membranes. The membranes were blocked of nonspecific antibody binding with
10% skim milk powder in phosphate-buffered saline, and probed with the
following primary antibodies: mouse anti-E2F2 antibody (1:2000) (sc-633×),
mouse anti-JMJD6 antibody (1:500) (sc-28348), mouse anti-N-Myc antibody
(1:1000) (sc-53993), or rabbit anti-c-Myc antibody (1:500) (sc-764) (all from Santa
Cruz Biotechnology). The membranes were then incubated with a horseradish
peroxidase-conjugated goat anti-rabbit or goat anti-mouse antibody (1:10000)
(both from Santa Cruz Biotechnology), and protein bands were visualized with
SuperSignal (Pierce). The membranes were finally probed with a mouse anti-actin
antibody (1:30000) (A3853, Sigma) as loading controls.
Affymetrix microarray gene expression study. DOX-inducible control shRNA,
JMJD6 shRNA-1 or JMJD6 shRNA-2 CHP134 or SK-N-AS cells were treated with
vehicle control or DOX for 40 h. RNA was extracted from the cells with RNeasy
Mini Kit (Qiagen), and genome-wide differential gene expression was examined
with Affymetrix microarrays using the Clariom S Human assay (Affymetrix, Santa
Clara, CA)29. The microarray data were analyzed in R [http://www.r-project.org/]
with bioconductor packages [http://www.bioconductor.org/] and normalized with
the robust multiarray average algorithm35, and differential expression analysis was
performed using the Limma package36. Moderated t tests were performed with the
Limma package and the false discovery rate (FDR) was controlled using the
Benjamini and Hochberg method37. Functional enrichment of the differentially
expressed genes was performed with GSEA38. The list of differentially expressed
genes were ranked by the log of the fold change and then compared with known
gene sets in the curated database Molecular Signature Database (MSigDB), in
particular, the C3: Motif gene sets database of genes sets39. A gene set was con-
sidered to be significantly enriched if its FDR q-value was below 0.25.
ChIP assays. For analyzing protein binding to gene promoters and enhancers, cells
were incubated with formaldehyde to cross-link protein and DNA. After cell lysates
were sonicated, a mouse anti-N-Myc (sc-53993, Santa Cruz Biotechnology), rabbit
anti-c-Myc (ab56, Abcam), mouse anti-RNA Pol II (664903, BioLegend, San Diego,
CA), mouse anti-CDK7 (sc-7344, Santa Cruz Biotechnology) antibody, or control
rabbit or mouse antibody were used to immunoprecipitate the DNA-protein
complex, followed by real-time PCR with primers targeting negative control
regions, the core promoter regions of the JMJD6 or the MYCN genes or the JMJD6
super-enhancer40. The sequences of primers used were: 5′-GGCAATATCATCA
CCCCCTA-3′ (forward) and 5′-GGCCAAGCTGATCTTGAACT-3′ (reverse) for
the remote negative control region of the JMJD6 gene; 5′-AGGAACCCAGCCA
AGTCAG-3′ (forward) and 5′-GCTTTCGATTCTCGGAGGAG-3′ (reverse) for
the JMJD6 gene promoter containing canonical and noncanonical E-boxes; 5′-
TTTGTTGAATGCGCAAGAG-3′ (forward) and 5′-GCCATCGTTATCCTCACC
AC-3′ (reverse) for the JMJD6 gene exon 2 region; 5′-TCTAGGTCCCACTGGCA
TTT-3′ (forward) and 5′-TGGTTTGAATGTGTCCTCCA-3′ (reverse) for the
remote negative control region of the MYCN gene; 5′-TGGGTTAGAAGCATCGG
TCT-3′ (forward) and 5′-CCTGGCAATTGCTTGTCATT-3′ (reverse) for the
MYCN gene promoter; 5′-CTCTCTCCCTCTCCCGACTT-3′ (forward) and 5′-
TGGGAGACACAGTGAACCAA-3′ (reverse) for the JMJD6 gene super-enhancer
region; and 5′-CGGTGAGCCAAGATCATACC-3′ (forward) and 5′-CGCCTG
ACGAGAAAAGACTC-3′ (reverse) for the JMJD6 gene intron 5 region. Fold
enrichment of the gene promoter or super-enhancer region was calculated by
dividing PCR products from samples immunoprecipitated by the experimental
antibody by PCR products from samples immunoprecipitated by the control
antibody.
ChIP-Seq. DOX-inducible control JMJD6 shRNA-2 CHP134 cells were treated
with vehicle control or DOX for 40 h, followed by ChIP with a mouse anti-RNA
Pol II antibody (664903, BioLegend) or control mouse IgG (sc-2025, Santa Cruz
Biotech). In addition, ChIP was performed in CHP134 cells with a rabbit anti-
H3K27ac antibody (ab4726, Abcam), rabbit anti-H3K4me antibody (ab106165,
Abcam), rabbit anti-H3K4me3 antibody (ab213224, Abcam), mouse anti-N-Myc
(sc-53993, Santa Cruz Biotechnology), rabbit anti-JMJD6 (ab64575, Abcam), or
control rabbit IgG (sc-2027, Santa Cruz Biotech). After immunoprecipitation, DNA
was purified and subjected to sequencing with Illumina HiSeq 2000 at Ramaciotti
Center for Genomics, University of New South Wales, Sydney, Australia.
ChIP-Seq raw reads were aligned using the Burrows Wheeler Aligner with
default parameters41. Files were further processed using SAMtools42, BEDtools43,
and bedGraphToBigWig44. Peaks were called with MACS2 “callpeak” (version
macs2 2.1.1.20160309) against input controls, with default parameters45.
Gene promoters were selected as ±1 kb from the transcription start site of genes
from the RefSeq (refFlat) database46, downloaded from the University of California
Santa Cruz Table Browser47. Enhancer and super-enhancer regions were identified
using the ROSE algorithm10,11,48. H3K27ac peaks within ±1000 bp of transcription
start sites were subtracted, enhancers were sutured at 12,500 bp in distance for
ranking, and a threshold for distinguishing enhancers and super-enhancers was
determined according to the geometric inflection point10,11,48. For enhancer and
super-enhancer gene associations, each gene was assigned a regulatory domain that
extends ±1000 kb in both directions to the nearest gene’s transcription start site
using the Genomic Regions Enrichment of Annotations Tool49. The two nearest
gene regions overlapping with a given enhancer or super-enhancer are listed
alongside each region. Promoters, enhancers and super-enhancers bound by N-
Myc or JMJD6 were selected if they overlapped with a ChIP-seq peak identified
from all three replicates of either N-Myc or JMJD6, and only peaks with FDR
q-value < 0.05 were retained for analysis.
To select genes with reduced RNA Pol II binding at their promoters after
DOX treatment in DOX-inducible JMJD6 shRNA-2 CHP134 cells, the following
steps were undertaken. Promoters with reduced RNA Pol II binding were selected
as those that had a RNA Pol II ChIP-Seq peak called within the region in both
replicates in vehicle control-treated samples, but no peak in either replicate in
DOX-treated samples. The statistical difference between normalized numbers of
RNA Pol II ChIP-Seq reads between vehicle control-treated samples and DOX-
treated samples was determined separately for each replicate using a paired t test.
The data points used to calculate statistical significance were “normalized ChIP-
Seq reads per kilobase,” determined using the following formula: total number of
reads overlapping region of interest/size of region of interest (base pairs)/
normalization factor × 1000, where normalization factor was equal to the number
of ChIP-seq reads in the file divided by the average number of ChIP-seq reads
across all files.
The resulting list of genes with promoters identified by the above analysis was
used as input for the GSEA, performed with the “Investigate Gene Sets” tool
available via the Broad Institute [http://software.broadinstitute.org/gsea/], and the
MSigDB38. Genesets with FDR q-value < 0.05 and p < 0.05 in Hallmark Gene Sets
were regarded as significantly regulated gene sets.
Protein co-immunoprecipitation assays. Protein was extracted from CHP134
cells and co-immunoprecipitation was carried out using a rabbit anti-BRD4 anti-
body (Bethyl Laboratories, Montgomery, TX), rabbit anti-JMJD6 antibody (Abcam
ab135066) or control IgG as a negative control, followed by immunoblot analysis
with anti-BRD4 and anti-JMJD6 antibodies. Protein co-immunoprecipitation was
also carried out with an anti-N-Myc antibody (Santa Cruz Biotechnology B8.4.b) or
control IgG as a negative control, followed by immunoblot analysis with the anti-
JMJD6 (Abcam Ab64575) and an anti-N-Myc antibodies.
GST pull-down assays. Different N-Myc protein fragments (1–86, 82–254,
249–358, 336–400, and 400–464 aa) were cloned into the pGEX-2T construct, in
frame with N-terminal GST50. The constructs were transformed into BL-21 E. Coli
and IPTG was used for induction of T7-driven transcription (4 h at 30 °C). GST-N-
Myc fragments were purified by using glutathione-agarose resin (Sigma - G4510).
HEK-293T cells were transiently transfected with pCMV14-JMJD6_3 × Flag
expression construct and nuclear protein from the cells was incubated with equal
amount of different GST-N-Myc protein fragments immobilized onto glutathione
agarose beads. Pulled-down complexes were analyzed by immunoblot with a
monoclonal anti-Flag antibody (F1804, Sigma) and Ponceau staining detected by
ChemiDoc MP (Bio-Rad) was used as loading controls.
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Alamar blue assays. Alamar blue assays were performed as we described pre-
viously40. Briefly, cells in 96-well plates were transfected with various siRNAs,
treated with vehicle control or DOX, or treated with vehicle control, THZ1 (CS-
3168, Chemscene LLC, Monmouth Junction, NJ), and/or panobinostat (S1030,
Selleckchem, Houston, TX). After 96 or 72 h, the cells were incubated with Alamar
blue (Invitrogen) for the last 5 h, and plates were read on a microplate reader at
570/595 nm. Results were calculated according to the optical density absorbance
units, and expressed as percentage changes in the number of viable cells, relative to
the samples transfected with control siRNA or control shRNA or treated with
vehicle control.
Cell cycle analysis. Neuroblastoma cells were treated with vehicle control, THZ1,
panobinostat, or combination of THZ1 and panobinostat for 72 h. In separate
experiments, DOX-inducible control shRNA, JMJD6 shRNA-1 or JMJD6 shRNA-2
neuroblastoma cells were treated with vehicle control or DOX for 72 h. Cells were
then collected and resuspended in solution containing 2 μg/ml RNase (Sigma) and
50 μg/ml propidium iodide at 2 × 106 cells/ml (Sigma). The cells were thereafter
examined by flow cytometry using FACS Calibur machine and FACS Diva software
(BD Biosciences). The percentage of cells at every phase of the cell cycle was
analyzed.
In vivo mouse experiments. Female Balb/c nude mice aged 5–6 weeks were
anesthetized and subcutaneously injected with 8 × 106 DOX-inducible JMJD6
shRNA-2 SK-N-AS cells (50% serum-free cell culture medium/50% matrigel) into
the right flank. Animals were excluded from experiments and analysis, if they did
not develop tumors. When tumors reached 0.05 cm3, mice were randomly divided
into two groups of 10–12 and fed with feed with or without 600 mg/kg DOX (Meat
Free Rat and Mouse Finished Diet, Specialty Feeds Pty. Ltd., Glen Forrest, WA,
Australia). Tumor development was monitored and tumor volume was calculated
using (length × width × height)/2. All efforts were taken to measure tumor size as
accurately as possible. When tumors reached 1.0 cm3, mice were culled and tumors
were collected. This mouse experiment was approved by the Animal Care and
Ethics Committee of UNSW Sydney, Australia, and animals’ care was performed in
agreement with institutional guidelines.
For the experimental therapy study, 72 male Balb/c nude mice aged 5–6 weeks
were anesthetized and subcutaneously injected with 6 × 106 SK-N-AS cells
transfected with empty vector or JMJD6 ORF expression construct (50% serum-
free cell culture medium/50% matrigel) into the right flank. When tumors reached
0.05 cm3, mice in the empty vector SK-N-AS xenograft group and the JMJD6 ORF
SK-N-AS xenograft group were each randomly divided into four subgroups of nice,
and treated intraperitoneally with vehicle control, THZ1 at 10 mg/kg body weight
twice every day, panobinostat at 7.5 mg/kg body weight once every three days, or
combination of THZ1 and panobinostat. Tumor size was monitored once every
other day. Mice were culled 21 days after the beginning of treatments, when tumors
in vehicle control group approached 1.0 cm3. The mice were purchased from the
Experimental Animal Center of Chinese Academy of Science (Shanghai, China).
The experiment was approved by the Shanghai University of Traditional Chinese
Medicine Committee on the Use of Live Animals for Teaching and Research, and
animals’ care was performed in accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health (publication No.
SCXX(HU) 2007–0005).
Analysis of 17q gain in human neuroblastoma tissues. Array-CGH data from
209 human neuroblastoma tissues were generated previously and downloaded from
the Gene Expression Omnibus website of the National Center for Biotechnology
Information (SuperSeries GSE45480)18. JMJD6 expression in the 209 human
neuroblastoma tissues were also published previously as a part of the Kocak dataset
and downloaded from the Gene Expression Omnibus website (SuperSeries
GSE45480)18.
To create the map of chromosome 17 copy number gains, the whole
chromosome was divided into bins of 100 kb and overlaps between intervals of
copy number gains and these bins were counted. Only intervals exceeding a copy
number of 2.5 were considered as gains. The frequency of gains among all
209 samples was plotted to show all bins across chromosome 17q.
Statistical analysis. For statistical analysis, experiments were performed at least
three times. Data were analyzed with Graphpad Prism 6 and expressed as mean ±
standard error. The variance was similar between the groups that were statistically
compared. Differences were examined for significance with two-sided unpaired t
test for two groups or ANOVA among groups.
Correlation between JMJD6 expression with N-Myc and c-Myc expression, as
well as correlation between JMJD6 expression and chromosome 17q gain, in
human neuroblastoma tissues was examined using Pearson’s correlation. Patient
overall survival was specified as the time from diagnosis till death or till last contact
if the patient did not die. Event-free survival was defined as the time from diagnosis
until the first occurrence of disease relapse, progression, death, or until last contact
if no event occurred. Survival analyses were performed according to the method of
Kaplan and Meier using GraphPad Prism 6.0, and comparisons of survival curves
were carried out using two-sided log-rank tests. Hazard ratios and survival
probabilities were provided with 95% confidence intervals (CIs). Proportionality
was verified by visual inspection of the plots of log(2 log(S(time))) versus log(time),
which remained parallel40. A probability value of 0.05 or less was considered
statistically significant.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The microarray data and the ChIP-Seq data have been deposited at the Gene Expression
Omnibus website with series numbers of GSE112914, GSE113139, and GSE112919,
respectively. All the other data supporting the findings of this study are available within
the article and its supplementary information files and from the corresponding author
upon reasonable request. A reporting summary for this article is available as a
Supplementary Information file. The source data underlying Figs. 1b–f, 2a–c, e, 3a–f, 4a-
d, 5a–d, 6c, d, 7a–f, and Table 1 and Supplementary Figs. 1a, b, 2a, b, 3a, d–g, 4a–d, 5a, b,
6a, b, and 7a, b are provided as a Source Data file. Array-CGH data from 209 human
neuroblastoma tissues and gene expression in the 209 human neuroblastoma tissues were
downloaded from the Gene Expression Omnibus website [https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE45480]18. Gene expression in 88 and 476 human
neuroblastoma samples and relevant patient prognosis information in the Versteeg and
Oberthuer datasets were downloaded from the R2 platform [http://r2.amc.nl].
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